Urgent action must be taken to address the dramatic rise of cancer drug prices and to better align prices with value, the President’s Cancer Panel urged in a recent report.
As NCI employees and others at HHS were receiving notices of termination, national cancer organizations called on Congress “to restore stability to NIH.”
